Perfil de los pacientes que acuden al médico internista para valoración de osteoporosis: registro OSTEOMED

Cabrera, José Antonio Blázquez; Henríquez, M. Sosa; Curiel, Manuel Dı́az; Moliní, Pilar Sánchez; García, Fernando Cano; Montoya, María; Filgueira, J.S.; Olmos, José Manuel; Coco-Martín, María Begoña; Castrillón, José Luis Pérez; Osteomed, en representación del; Osteomed, Anexo Componentes del grupo

doi:10.1016/j.rce.2020.06.004

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La osteoporosis es una enfermedad con alta prevalencia e importante repercusión en la salud pública en nuestra sociedad, sobre todo por ocasionar limitación funcional y alteración severa de la calidad de vida de los pacientes 1 , así como por su asociación con un aumento de la morbilidad y de la mortalidad cuando provoca fracturas y sus complicaciones 2 .…”

unclassified

Cumplimiento de las medidas preventivas de osteoporosis en atención primaria

2022

View full text Add to dashboard Cite

unclassified

Cumplimiento de las medidas preventivas de osteoporosis en atención primaria

2022

View full text Add to dashboard Cite

Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry

Coco-Martín,

Leal-Vega,

Blázquez-Cabrera

et al. 2023

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Purpose To evaluate the effect of different non-osteoporotic drugs on the increase or decrease in the risk of incident fragility fractures (vertebral, humerus or hip) in a cohort of patients diagnosed with osteoporosis on active anti-osteoporotic therapy. Methods For this retrospective longitudinal study, baseline and follow-up data on prescribed non-osteoporotic treatments and the occurrence of vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzed using logistic regression models. The drugs evaluated with a possible beneficial effect were thiazides and statins, while the drugs evaluated with a possible harmful effect were antiandrogens, aromatase inhibitors, proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, GnRH agonists, thyroid hormones, and oral and inhaled corticosteroids. Results Logistic regression analyses indicated that no treatment significantly improved fracture risk, with the only treatments that significantly worsened fracture risk being letrozole (OR = 0.18, p-value = 0.03) and oral corticosteroids at doses ≤ 5 mg/day (OR = 0.16, p-value = 0.03) and > 5 mg/day (OR = 0.27, p-value = 0.04). Conclusion The potential beneficial or detrimental effects of the different drugs evaluated on fracture risk are masked by treatment with anabolic or antiresorptive drugs that have a more potent action on bone metabolism, with two exceptions: letrozole and oral corticosteroids. These findings may have important clinical implications, as patients receiving these treatments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs such as denosumab or teriparatide.

show abstract

Perfil de los pacientes que acuden al médico internista para valoración de osteoporosis: registro OSTEOMED

Cited by 2 publications

References 25 publications

Cumplimiento de las medidas preventivas de osteoporosis en atención primaria

Cumplimiento de las medidas preventivas de osteoporosis en atención primaria

Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry

Contact Info

Product

Resources

About